News
Synta stock surges on drug-test news - The Boston Globe
archive.boston.com
In the first phase of clinical trials, more than 70 percent of patients showed “a high disease-control rate,'' said Vojo Vukovic, Synta's chief ...
Synta Announces Encouraging STA Clinical Results Presented at...
www.finanznachrichten.de
– STA well-tolerated in Phase 1 solid tumor studies at dose levels up to 216mg/m2 – – Promising single-agent clinical activity observed across multiple
Synta Pharma Appoints Vojo Vukovic SVP And Chief Medical Officer -...
www.rttnews.com
(SNTA) appointed Vojo Vukovic as Senior Vice President and Chief Medical Officer of the company. Vukovic replaces Eric Jacobson, who ...
Latest news about Vojo Vukovic - Stock Market | International...
markets.ibtimes.com
The International Business Times is the leading provider of international business news online.
sorted by relevance / date